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Antiplatelet drugs for secondary prevention
in patients with ischemic stroke or
transient ischemic attack: a systematic
review and network meta-analysis
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Abstract
Background: Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but their relative
effectiveness and harms still need to be clarified. Within this network meta-analysis we aimed to summarize the
current evidence for using antiplatelet drugs for secondary stroke prevention.
Methods: We searched MEDLINE, EMBASE and CENTRAL up to September 2020. Randomized controlled trials
(RCTs) assessing antiplatelet drugs for secondary stroke prevention were included. We did pairwise meta-analyses
and network meta-analyses using random-effects models. Primary outcomes were all strokes (ischemic or
hemorrhagic) and all-cause mortality.
Results: The review included 57 RCTs, 50 (n = 165,533 participants) provided data for the meta-analyses. Compared
to placebo/no treatment, moderate to high-confidence evidence indicated that cilostazol, clopidogrel, dipyridamole +
aspirin, ticagrelor, ticlopidine, and aspirin≤ 150mg/day significantly reduced the risk of all strokes (odds ratios, ORs and
absolute risk difference, ARD): cilostazol 0.51 (95 % confidence interval, CI, 0.37 to 0.71; 3.6 % fewer), clopidogrel 0.63
(95 % CI, 0.49 to 0.79; 2.7 % fewer), dipyridamole + aspirin 0.65 (95 % CI, 0.55 to 0.78; 2.5 % fewer), ticagrelor 0.68 (95 %
CI, 0.50 to 0.93; 2.3 % fewer), ticlopidine 0.74 (95 % CI 0.59 to 0.93; 1.9 % fewer), aspirin≤ 150mg/day 0.79 (95 % CI, 0.66
to 0.95; 1.5 % fewer). Aspirin > 150mg/day and the combinations clopidogrel/aspirin, ticagrelor/aspirin, also decrease all
strokes but increase the risk of hemorrhagic events. Only aspirin > 150mg/day significantly reduced all-cause mortality
(OR 0.86, 95 % CI 0.76 to 0.97; ARD 0.9 %, 95 %CI 1.5–0.2 % fewer, moderate confidence). Compared to aspirin≤ 150
mg/day, clopidogrel significantly reduced the risk of all strokes, cardiovascular events, and intracranial hemorrhage
outcomes. Cilostazol also appeared to provide advantages but data are limited to the Asian population.
Conclusions: Considering the benefits and harms ratio, cilostazol, clopidogrel, dipyridamole + aspirin, ticagrelor,
ticlopidine, and aspirin≤ 150mg/day appear to be the best choices as antiplatelet drugs for secondary prevention of
patients with ischemic stroke or TIA.
Systematic review registration: PROSPERO CRD42020159896.
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Background
Despite a pronounced decrease in age-standardized mor-
tality rates, stroke burden remains high. People living
with stroke in the European Union is estimated to in-
crease by one third between 2017 and 2047. This shift in
stroke burden from mortality to morbidity depends on
demographics change over time, implementation of pri-
mary prevention strategies, and availability of better care
and treatment both in the acute and long-term stages
after stroke [1].
The annual risk for future ischemic stroke after a
stroke or transient ischemic attack (TIA) is 3–5 %, ac-
counting for 25–30 % of all strokes. These patients are
also at higher risk for subsequent myocardial infarction
and death from vascular causes [2–5].
The risk of stroke is highest in the early period after
the acute event. Prompt initiation of tailored prevention
strategies, e.g., referral to acute stroke units, immediate
antithrombotic drugs, early carotid revascularisation, is
essential. In the longer term, optimal medical therapy,
including antiplatelet and statin therapy, and risk factor
modification, are recommended [4, 6]. The initiation or
resumption of antihypertensive therapy, accompanied by
lifestyle modifications, may be beneficial for patients
with known hypertension [6].
Appropriate antithrombotic medication should be
carefully chosen considering the ischemic injury physio-
pathological mechanism: antiplatelet drugs are preferred
for lesions characterized by atherosclerosis and vascular
injury, whereas anticoagulant medications are indicated
for cardioembolisms and thrombophilic conditions [7].
Antiplatelet drugs are widely recommended for non-
cardioembolic stroke. Different drugs are currently used
as monotherapies or combination therapies for preven-
tion of vascular events among patients with stroke or
TIA, given their effect in reducing the risk of stroke,
myocardial infarction and death [6, 8]. Historically, the
role of aspirin in preventing any type of stroke among
patients with a recent stroke or TIA has been demon-
strated, with a similar magnitude of benefit for doses
ranging from 75 to 1500mg but a marked difference in
toxicity. Platelet Adenine di-Phosphate receptor antag-
onist, as ticlopidine and clopidogrel, and dual-therapies,
as the combination of aspirin and dipyridamole were
shown to be effective for secondary stroke prevention
[4]. Newer agents, such as ticagrelor, may offer pharma-
cokinetics advantages over similar drugs. However, the
relative effectiveness of these approaches is unclear, and
the different safety profile, costs, patient characteristics,
and preferences may affect the selection among agents
for long-term secondary prevention.
Network meta-analysis (NMA) includes multiple inter-
ventions within a single analysis and allows researchers
to estimate the relative treatment effect between each
two treatments, also those that have never been com-
pared in a trial, by using direct and indirect evidence [9].
NMA also allows ranking drugs by benefits and harms
[10], and thus are used in clinical guidelines to support
recommendations [11]. Current NMA on antiplatelet
drugs for secondary prevention of stroke focused only
on a limited number of treatments and did not include a
thorough assessment of the confidence in the estimates
[12–17]. Therefore, we conducted a NMA to summarize
the current evidence for using antiplatelet drugs for sec-
ondary prevention in adult patients with ischemic stroke
or TIA by estimating their relative efficacy and safety
and providing a clinically useful ranking to help clini-




The systematic review protocol, registered in PROS-
PERO (CRD42020159896) [18] was developed following
the Preferred Reporting Items for Systematic Review and
Meta-analysis Protocols (PRISMA-P) statement [19]. We
used the PRISMA-network meta-analysis extension to
report the results [20].
Search strategy and selection criteria
We searched MEDLINE, EMBASE, and the Cochrane
Central Register of Controlled Trials (CENTRAL) elec-
tronic databases from inception date to September 2020,
with no language restrictions. The full search strategies
is available on PROSPERO [18]. We searched Clinical-
Trials.gov for ongoing studies (January 2016-December
2020).
Eligibility criteria
We included randomized controlled trials (RCTs) com-
paring any antiplatelet drug at any dose, as monotherapy
or combination therapy, with either a control (placebo/
no treatment) or another antiplatelet drug at any dose,
as monotherapy or combination therapy, for secondary
prevention in adults (≥ 18 years old, both sexes) with is-
chemic stroke or TIA in which hemorrhage had been
ruled out. We included all settings of care (e.g., acute or
nursing homes, hospitals or ambulatory, etc.), as well as
both acute and delayed treatments. We excluded RCTs
comparing different doses of the same drug if no other
eligible comparator was included, and those not provid-
ing outcome data on a specific antiplatelet drug. We in-
cluded reports published in English or Italian. Two
authors independently performed study selection and
data extraction; any discrepancy was resolved by consen-
sus and arbitration by a third author. We excluded from
the statistical analyses studies with a total sample size <
100 participants because they are likely to produce
Del Giovane et al. BMC Neurology          (2021) 21:319 Page 2 of 10
biased estimated and overestimate the treatment effect
[21]. This is a variation of the protocol [18].
Outcomes
Primary outcomes were all-cause mortality and the pro-
portion of patients who developed a stroke, irrespective
of its type (ischemic or hemorrhagic) and severity. Sec-
ondary outcomes included proportion of patients who
developed: ischemic stroke; ischemic stroke or TIA irre-
spective of severity; cardiovascular events; hemorrhagic
strokes; intracranial hemorrhages; major bleeding. Sup-
plementary 1 reports secondary outcomes definitions.
We extracted outcome data at the longest available
follow-up. Network plots were used to describe the net-
work geometry [22].
Risk of bias assessment and confidence in the evidence
One reviewer evaluated the risk of bias for included
study using the criteria of The Cochrane Collaboration
[23]. This appraisal was independently checked by a sec-
ond reviewer. We judged the confidence in the evidence
derived from NMA for primary and secondary outcomes
using the web application CINeMA (http://cinema.ispm.
ch/) [24]. Supplementary 1 reports the methodology for
the risk of bias and confidence in the evidence
assessment.
Statistical analyses
We measured treatment effects using the odds ratio
(OR) with 95 % confidence intervals (95 % CIs). For all
outcomes with at least two studies, we performed stand-
ard pairwise meta-analyses of any antiplatelet drug ver-
sus placebo/no treatment with a random-effects model.
We compared different antiplatelets through NMA per-
formed under a frequentist framework using a random-
effects model. Results of NMAs were presented in league
tables and forest plots. For each outcome, we calculated
the probability of each treatment to be the best among
all treatments by using the surface under the cumulative
ranking curve area (SUCRA) [10]. We presented the re-
sults from pairwise meta-analyses and NMAs as sum-
mary relative effect sizes. We reported absolute risk
difference (ARD) estimates, calculated using as baseline
the proportion of patients with an event in the control
arm (i.e., placebo/no treatment) of the included studies,
and applying the OR estimated in the NMA to compute
the absolute difference between the intervention and
control arms within GRADEPro [25].
We estimated heterogeneity variances for each pair-
wise comparison in standard pairwise meta-analyses and
assess the presence of statistical heterogeneity by visually
inspecting the forest plots and calculating the I-squared
statistic [26]. In NMA, we assumed a common estimate
for heterogeneity variance across comparisons and based
our assessment of statistical heterogeneity in the whole
network on the magnitude of the common heterogeneity
parameter [27]. We evaluated statistical disagreement
between direct and indirect effect sizes (incoherence) in
local and global approaches [28]. Locally, we used the
node-splitting approach [29]; we used the ‘design-by-
treatment’ Q-statistic in the entire network [28]. When
we found moderate heterogeneity or incoherence, we ex-
plored the impact of potential effect modifiers at study
and patient-level with subgroup analyses.
We considered the following potential effect modifiers:
age, gender, stroke subtypes at inclusion based on TOAST
classification (cardioembolic and non-cardioembolic ver-
sus non-cardioembolic only) [30], time from the first is-
chemic event to randomization (< 7 days versus ≥ 7 days),
and treatment duration (< 1month versus ≥ 1month). We
performed sensitivity analyses of any antiplatelet drug ver-
sus placebo/no treatment for each primary outcome, in-
cluding only trials that were classified as having a low risk
of bias, and only trials in which neuroimaging was used to
exclude hemorrhagic stroke at inclusion.
Results
A total of 1,886 citations were identified by the search,
and 81 potentially eligible articles were retrieved in full
text (Fig. 1). Overall, 57 trials were included in the re-
view (Supplementary 2). We excluded from the statis-
tical analysis one study that did not report any data on
the pre-defined selected outcomes [31], and six studies
[32–37] with a sample size < 100 participants. The
remaining 50 studies (n = 165,533 patients) were in-
cluded in our quantitative analysis. Supplementary 2
summarizes the characteristics of the 57 included trials,
published between 1978 and 2020. Twenty-eight of 57
(49 %) studies randomized patients with ischemic stroke
or TIA as index event, 25 (44 %) with ischemic stroke,
and four (7 %) with TIA only. Thirty-nine (68 %) trials
included only patients with non-cardioembolic strokes.
The included studies assessed the effect of 21 different
antiplatelet drugs or combinations. The median follow-
up period was 18months (range, 7 days – 4 years). Over-
all, 30 (53 %) trials were rated as low risk of bias, 18
(32 %) as moderate, and 9 (16 %) as high risk (Supple-
mentary 3). We also identified four ongoing studies
(Supplementary 4).
Figure 2 and Supplementary 5 shows the network
geometry for each primary and secondary outcome, re-
spectively. Results from pairwise meta-analysis for each
primary and secondary outcome are reported in Supple-
mentary 6. Figure 3 shows the estimates of primary and
secondary outcomes of each antiplatelet/combination of
antiplatelet drugs against placebo/no treatment from the
NMA, with the corresponding confidence in the evi-
dence. The league tables including results from the
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NMA for each treatment compared to other treatments
are reported in the Supplementary excel file.
Thirty-seven RCTs (147,742 participants) addressed all
stroke outcome comparing an antiplatelet drug or com-
bination versus placebo/no treatment or another anti-
platelet drug/combination. Moderate to high-confidence
in evidence indicated that cilostazol, clopidogrel alone
and in combination with aspirin, ticagrelor alone and in
combination with aspirin, dipyridamole in combination
with aspirin, ticlopidine and aspirin both ≤ 150 and >
150 mg/day were significantly associated with the great-
est benefits when compared with placebo/no treatment
(Fig. 3). OR estimates ranged from 0.51 (cilostazol) to
0.84 (aspirin > 150 mg/day), corresponding to ARD from
3.6 to 1.1 % fewer strokes. When compared with as-
pirin ≤ 150 mg/day, only clopidogrel (with high confi-
dence), clopidogrel plus aspirin and cilostazol (with
moderate confidence) significantly reduced the risk of all
strokes (OR range from 0.65 to 0.79, corresponding to
an ARD from 2.7 to 1.6 % fewer strokes (Supplementary
7). The common standard deviation heterogeneity esti-
mate was 0.11.
Forty-two RCTs (154,016 participants) addressed all-
cause mortality. Only aspirin > 150 mg/day significantly
reduced all-cause mortality compared to placebo/no
treatment (OR 0.86, 95 % CI 0.76 to 0.97; ARD 0.9 %,
95 % CI 1.5–0.2 % fewer, moderate confidence). Moder-
ate to high-confidence in evidence indicated that
Fig. 1 Study selection
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ticlopidine and dipyridamole in combination with aspirin
could reduce all-cause mortality, with OR estimates
below 0.9 versus placebo/no treatment, although not sig-
nificant (Fig. 3). No drug was significantly more effective
than aspirin ≤ 150 mg/day. The common standard devi-
ation heterogeneity estimate was 0.07.
Thirty-nine RCTs (148,414 participants) addressed
ischemic stroke. Moderate to high-confidence in evi-
dence indicated that clopidogrel alone and in combin-
ation with aspirin, cilostazol, ticagrelor alone and in
combination with aspirin, dipyridamole in combin-
ation with aspirin, ticlopidine and aspirin both ≤ 150
and > 150 mg/day were significantly associated with
the greatest benefits compared with placebo/no treat-
ment (Fig. 3). OR estimates ranged from 0.54 (clopi-
dogrel in combination with aspirin) to 0.77 (aspirin >
150 mg/day), corresponding to ARD from 2.0 to 1.0 %
fewer ischemic stroke. In comparison with aspirin ≤
150 mg/day, we found high confidence in the benefit
for clopidogrel in combination with aspirin and mod-
erate confidence for cilostazol and ticagrelor in com-
bination with aspirin (OR range from 0.73 to 0.78,
corresponding to ARD from 1.9 to 1.5 % fewer ische-
mic stroke) (Supplementary 7). The common standard
deviation heterogeneity estimate was 0.09.
Thirty-nine RCTs (146,202 participants) addressed
cardiovascular events. Moderate to high-confidence in
evidence indicated that clopidogrel alone and in combin-
ation with aspirin, cilostazol, dipyridamole in combin-
ation with aspirin, ticagrelor, ticlopidine and aspirin
both ≤ 150 and > 150 mg/day were significantly associ-
ated with the greatest benefits versus placebo/no treat-
ment (Fig. 3). OR estimates ranged from 0.64
(clopidogrel in combination with aspirin) to 0.84
(aspirin ≤ 150 mg/day), corresponding to ARD from 3.3
to 1.4 % fewer cardiovascular events. In comparison with
aspirin ≤ 150 mg/day, clopidogrel and dipyridamole in
combination with aspirin (with high confidence), and
cilostazol (with moderate confidence) were significantly
more beneficial (OR range from 0.76 to 0.82, corre-
sponding to ARD from 2.3 to 1.7 % fewer cardiovascular
event), while indobufen was more harmful (OR 1.86,
95 % CI 1.09 to 3.17, ARD 7.4 %, 95 % CI 0.8–16.5 %
more cardiovascular events; high confidence) (Supple-
mentary 7). The common standard deviation heterogen-
eity estimate was 0.03.
Thirty-one RCTs (130,274 participants) addressed
hemorrhagic stroke. No drug was significantly more ef-
fective than placebo/no treatment (Fig. 3). High-
confidence in evidence indicated that cilostazol signifi-
cantly reduced hemorrhagic stroke in comparison with
aspirin ≤ 150 mg/day (OR 0.42 95 % CI 0.19 to 0.92,
ARD 0.2 %, 95 % CI 0.3–0 % fewer hemorrhagic strokes)
(Supplementary 7). Conversely, vorapaxar (with high
confidence) and ticagrelor in combination with aspirin
(with moderate confidence) were significantly associated
with the greatest harms when compared with placebo/
no treatment. OR estimates ranged from 2.85 (vorapaxar
vs. placebo added to standard antiplatelet therapy) to
6.02 (ticagrelor in combination with aspirin), corre-
sponding to ARD from 1.4 to 3.7 % more hemorrhagic
strokes) (Fig. 3). When compared with aspirin ≤ 150mg/
day, ticagrelor in combination with aspirin was signifi-
cantly associated with the greatest harms (OR 4.98, 95 %
CI 1.08 to 23.01, ARD 1.6 %, 95 % CI 0–8.4 % more
hemorrhagic strokes, with moderate confidence) (Sup-
plementary 7). The common standard deviation hetero-
geneity estimate was 0.10.
Fig. 2 Network plots of evidence for primary outcomes: each line links the treatments that have been directly compared in studies. The thickness
of the line is proportional to the precision of each direct estimate, and the width of each circle is proportional to the number of studies included
in the treatment
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Twenty-seven RCTs (106,309 participants) addressed
intracranial hemorrhage. No drug was more beneficial
than placebo/no treatment (Fig. 3), while cilostazol (OR
0.30 95 % CI 0.16 to 0.59, ARD 0.5 % 95 % CI 0.7–0.3 %
fewer intracranial hemorrhage, high confidence) and clo-
pidogrel (OR 0.62 95 % CI 0.39 to 0.96, ARD 0.3 % 95 %
CI 0.5–0 % fewer intracranial hemorrhages, moderate
confidence) were significantly more beneficial than as-
pirin ≤ 150 mg/day (Supplementary 7). Moderate to
high-confidence in evidence indicated that vorapaxar,
terutroban, aspirin > 150 mg/day and ticagrelor in com-
bination with aspirin were significantly associated with
the greatest harms versus placebo/no treatment (Fig. 3).
OR estimates ranged between 2.54 (vorapaxar vs. pla-
cebo added to standard antiplatelet therapy) to 7.02
(ticagrelor in combination with aspirin), correspond-
ing to ARD from 1.1 to 4.2 % more intracranial hem-
orrhages. In comparison with aspirin ≤ 150 mg/day,
only ticagrelor in combination with aspirin was sig-
nificantly more harmful (OR 3.32 95 % CI 1.33 to
8.28, ARD 1.8 % 95 % CI 0.3–5.3 % more intracranial
hemorrhages; high confidence) (Supplementary 7).
The common standard deviation heterogeneity esti-
mate was almost null.
Fig. 3 Forest plot of network estimates of primary (A) and secondary (B) outcomes of each antiplatelet/combination of antiplatelet drugs against
placebo/no treatment from the network meta-analysis, with the corresponding confidence in the evidence
Del Giovane et al. BMC Neurology          (2021) 21:319 Page 6 of 10
Forty RCTs (146,826 participants) addressed major
bleeding. No drug significantly reduced the risk of major
bleeding when compared with placebo/no treatment
(Fig. 3). High-confidence in evidence indicated that di-
pyridamole, cilostazol and triflusal significantly reduced
the risk of the outcome in comparison with aspirin ≤
150 mg/day. OR estimates ranged between 0.25 (dipyrid-
amole) to 0.37 (cilostazol and triflusal), corresponding to
ARD from 1.0 to 0.9 % fewer events of major bleeding
(Supplementary 7). Moderate to high-confidence in evi-
dence indicated that dipyridamole in combination with
aspirin, aspirin both ≤ 150 and > 150 mg/day, terutroban,
vorapaxar, clopidogrel in combination with aspirin and
ticagrelor in combination with aspirin were significantly
associated with the greatest harms versus placebo/no
treatment. OR estimates ranged from 1.67 (clopidogrel
in combination with aspirin) to 7.94 (ticagrelor in com-
bination with aspirin), corresponding to ARD from 0.8
to 7.5 % more events of major bleeding (Fig. 3). In com-
parison with aspirin ≤ 150 mg/day, clopidogrel in com-
bination with aspirin (OR 1.65 95 % CI 1.15 to 2.37,
ARD 0.9 % more 95 % CI 0.2–1.8 % more; high confi-
dence) and ticagrelor in combination with aspirin (OR
3.99 95 % CI 1.56 to 10.22, ARD 3.9 % more 95 % CI
0.8–11.2 % more events of major bleeding; high confi-
dence) were significantly associated with the greatest
harms (Supplementary 7). The common standard devi-
ation heterogeneity estimate was 0.23.
We did not perform NMA for ischemic stroke or TIA
outcome as it was assessed only by 11 RCTs (17,342 par-
ticipants) and only two comparisons had at least two
studies. This resulted in a disconnected network (see the
network plot in Supplementary 5). Results from standard
pairwise meta-analysis are available in Supplementary 6.
SUCRA, absolute probability to be the best treatment,
and the mean rank are reported in Supplementary 8. Re-
sults from the assessment of incoherence are showed in
Supplementary 9.
We compared the magnitude of the heterogeneity esti-
mates with the empirical distributions of heterogeneity
values derived by Turner [27] for objective (all-cause
mortality only) and semi-objective outcomes, for com-
parisons of treatments versus placebo. Our heterogeneity
estimates, except for major bleeding, were below the me-
dian of the empirical distributions of heterogeneity
values. Therefore, given the small heterogeneity and lit-
tle incoherence for all outcomes except those for major
bleeding, subgroup analyses (stroke subtypes; time from
first ischemic event to randomization; and treatment
duration) were performed for the major bleeding out-
come only (see results in Supplementary excel file). Sub-
group analyses for age and gender were not performed
because of scarce available data. Results from the sensi-
tivity analyses for primary outcomes are also reported in
Supplementary excel file. The comparison-adjusted fun-
nel plots for each outcome are reported in Supplemen-
tary 10.
Discussion
In this systematic review and NMA we found that cilos-
tazol, clopidogrel alone and in combination with aspirin,
ticagrelor alone and in combination with aspirin, dipyr-
idamole in combination with aspirin, ticlopidine, and as-
pirin both ≤ 150 and > 150 mg/day are significantly
associated with the greatest benefits in terms of recur-
rent stroke (both ischemic and hemorrhagic considered
together, and ischemic alone) and cardiovascular event
risk reduction compared to placebo/no treatment. The
absolute risk reductions range between 1.1 and 3.6 % for
recurrent strokes and between 1.4 and 3.3 % for cardio-
vascular events. However, ticagrelor in combination with
aspirin is significantly associated with the greatest harms
in terms of increased risk of hemorrhagic stroke (abso-
lute risk increase of 3.7 %), intracranial hemorrhage (ab-
solute risk increase of 4.2 %), and major bleeding
(absolute risk increase of 7.5 %) compared to placebo/no
treatment. Furthermore, clopidogrel in combination with
aspirin significantly increases the risk of major bleeding,
with an absolute risk increase of 0.8 %. Aspirin > 150 mg/
day compared to aspirin ≤ 150 mg/day and combination
therapies with aspirin vs. corresponding monotherapies,
do not show consistent increased benefits while possible
increased harms. Thus, considering the benefits and
harms ratio, cilostazol, clopidogrel, ticagrelor and ticlo-
pidine alone, aspirin ≤ 150 mg/day, and dipyridamole in
combination with aspirin, appear to be the best anti-
platelet drugs for secondary prevention of patients with
ischemic stroke or TIA. Low-dose aspirin is the most
widely used first-line antiplatelet drug for secondary pre-
vention of ischemic stroke, given the large body of evi-
dence supporting its efficacy in reducing the risk of
stroke, cardiovascular events, and certain cancers [38, 8].
Thus, we also explored the relative effect of antiplatelet
drugs compared to aspirin ≤ 150 mg/day. This NMA
suggests that clopidogrel significantly reduces the risk of
all strokes, cardiovascular event and intracranial haem-
orrhage outcomes, and cilostazol provide advantages on
all outcomes, except for all-cause mortality, over as-
pirin ≤ 150 mg/day. However, all the studies that evalu-
ated cilostazol involved Asian population, thus limiting
the generalizability of the results to the Caucasic popula-
tion. Indeed, the clinical use of cilostazol for stroke pre-
vention is limited to the Asia-Pacific countries, while in
the US and Europe it is approved for intermittent claudi-
cation only. In our NMA, antiplatelet drugs do not seem
to modify all cause-mortality. This effect may be due to
a genuine result or to a lack of sufficient precision of the
estimates, as suggested by the GRADE assessment. A
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possible exception could be aspirin > 150 mg/day that is
associated with a small decrease of all-cause mortality.
However, this effect was not significant when only stud-
ies at low risk of bias are considered. Nevertheless, if
any, the effect of aspirin on mortality can be due to
mechanisms other than its specific antiplatelet function,
for instance its effect on cancer mortality [38].
Comparison with other studies
To our knowledge, the first NMA on antiplatelet drugs
used after TIA or stroke was published in 2008 and in-
cluded 24 studies, involving more than 42,000 participants
[39]. The combination of aspirin and dipyridamole
emerged as the most effective regimen in preventing vas-
cular events. Six further NMAs were published by Chinese
authors between 2015 and 2019 [12–17]. Although minor
differences in terms of included studies, five reviews
agreed on suggesting that cilostazol is the most effective
drug. One NMA concluded in favor of clopidogrel and as-
pirin and their combination [16].
Overall, our NMA confirms these findings, providing a
relevant update up to 2020. While Xiang et al. concluded
that further studies are needed to confirm their findings,
[14] we found high confidence on the efficacy of cilosta-
zol and clopidogrel. According to the GRADE method-
ology, this means that it is unlikely that further research
will change the direction and magnitude of these
estimates.
Our NMA includes 50 RCTs providing data useful for
the NMA (over 165,000 participants) compared to the
previous systematic reviews that included from 24 [15]
to 45 [14] studies.
Moreover, it assessed the effect on several outcomes of
promising interventions such as ticagrelor, that has been
recently approved by the FDA to reduce the risk of
stroke in patients with acute ischemic stroke or high-
risk TIA [40]. A recent NMA – published only as ab-
stract – also assessed ticagrelor suggesting that as mono-
therapy it has a similar efficacy and safety profile than
clopidogrel [41]. We included a thorough assessment of
the confidence of estimates, i.e., that the measured ef-
fects are correct or adequate to support a particular de-
cision or recommendation [42], according to the
GRADE approach for NMA. This framework includes
the assessment of the classical five dimensions (within-
study bias, reporting bias, indirectness, imprecision, and
heterogeneity) considering the complexity of the net-
work. Moreover, it includes the assessment of the inco-
herence, that is the statistical manifestation of
intransitivity, the measure of the disagreement from dir-
ect and indirect evidence [43]. We also found small het-
erogeneity for all outcomes, except for major bleeding
for which subgroup analyses showed robust results com-
pared to the overall.
Limitations of this review
Our study has some limitations. First: many direct treat-
ment comparisons in our network were based on one
study only. Second: most of the treatments included in
our network were compared with placebo/no treatment
or aspirin only and the number of comparisons with an
active drug versus another active drug was quite small;
this means that our evidence was often a result of an in-
direct evidence only. Third, our NMA, principally based
on trials including only patients with non-cardioembolic
ischemic strokes, cannot inform the use of antiplatelet
drugs in different stroke subtypes that are associated to
variable pattern of stroke recurrence [44]. Fourth: sub-
group data were not adequate in terms of number of
studies and treatment included to assess treatment ef-
fects in the acute phase. Current guidelines recommend
dual antiplatelet therapy in the first 90 days after ische-
mic stroke or TIA [6] however, in our NMA, only 12
studies limit the duration of follow-up to the first 3
months after the acute event. Therefore, our conclusions
should be limited to long-term secondary prevention
only.
Conclusions
In conclusion, cilostazol, clopidogrel, ticagrelor and
ticlopidine alone, aspirin ≤ 150 mg/day, and dipyridamole
in combination with aspirin, appear to be the best anti-
platelet drugs for secondary prevention of patients with
ischemic stroke or TIA. The choice of drug will take into
account the characteristics of the individual patient, for
example ethnicity (data on cilostazol are limited to the
Asian population), allergies and comorbidities (thieno-
pyridines are not indicated in patients with severe liver
disease). This up-to-date, comprehensive and accurate
assessment of the effectiveness and safety of a broad
spectrum of treatments may be useful to support appro-
priate choices, both at individual and public health level,
informing drug prescribing and procurement.
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